Turn Therapeutics' Eczema Drug GX-03 Shows 92.6% Efficacy in Phase 2 Interim Data
TTRX has more than doubled off its 52-week low of $2.57 on elevated volume (6.2× avg).
Summary
Turn Therapeutics reported strong interim Phase 2 clinical trial results for its lead eczema drug candidate, GX-03. The study showed 92.6% of treated subjects achieved at least a 50% reduction in eczema severity within four weeks, significantly outperforming the 65.2% for the control group, alongside a favorable safety profile. This follows an 8-K filing and another news report earlier today announcing the positive interim results. The company is now preparing for FDA interactions to discuss regulatory strategy and potential pathways for advancement, which is a critical next step for the drug's development.
At the time of this announcement, TTRX was trading at $6.56 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $195.3M. The 52-week trading range was $2.57 to $26.50. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.